Results 251 to 260 of about 173,452 (291)
Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers. [PDF]
Collinson, P
core +1 more source
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick +13 more
wiley +1 more source
Creatine Kinase Surge: Levetiracetam-Induced Rhabdomyolysis. [PDF]
Romero KN +3 more
europepmc +1 more source
French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault +51 more
wiley +1 more source
CREATINE KINASE IS ELEVATED BY THE SUBMANDIBULAR VEIN BLEED TECHNIQUE, OBSCURING THE MEASUREMENT OF MUSCLE DAMAGE IN SEPSIS. [PDF]
Ali T +5 more
europepmc +1 more source
Gossypiboma‐associated sarcomas in five cases
Objectives To report clinical presentation, treatment and outcome of dogs and cats diagnosed with gossypiboma‐associated sarcoma. Materials and Methods Referral centres within the United Kingdom, Europe, North America and Australia were contacted to search medical records for dogs and cats with documented gossypiboma‐associated sarcoma and included if ...
G. Thomas +8 more
wiley +1 more source
Creatine kinase levels, carcass, and physicochemical properties of breast meat from traditionally slaughtered village chickens. [PDF]
Gunya B, Mdletshe ZM.
europepmc +1 more source
ABSTRACT Pharmacokinetics (PK) of intramuscular (IM) and subcutaneous (SC) ketamine in horses has not been described. This study aimed to evaluate the PK and safety of ketamine and its metabolites after a single SC or IM administration. In Phase 1, two horses received 0.5 or 1 mg/kg of ketamine via SC and IM routes.
Ana Rangel +5 more
wiley +1 more source

